Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial

2020 ◽  
Vol 7 (11) ◽  
pp. e808-e815 ◽  
Author(s):  
Bruce D Cheson ◽  
Nancy L Bartlett ◽  
Betsy LaPlant ◽  
Hun J Lee ◽  
Ranjana J Advani ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Brentuximab Vedotin ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 7542-7542 ◽  
Author(s):  
Jonathan W. Friedberg ◽  
Andres Forero-Torres ◽  
Beata Holkova ◽  
Jerome H. Goldschmidt ◽  
Ralph V. Boccia ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Hodgkin Lymphoma ◽  
Brentuximab Vedotin ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Long Term Follow Up

DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer

Lung Cancer ◽  
2014 ◽  
Vol 85 (2) ◽  
pp. 224-229 ◽  
Author(s):  
Joachim von Pawel ◽  
Vera Gorbounova ◽  
Martin Reck ◽  
Dariusz M. Kowalski ◽  
Aurore Allard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy

scholarly journals EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma

2015 ◽  
Vol 26 (6) ◽  
pp. 1118-1123 ◽  
Author(s):  
I.D. Davis ◽  
A. Long ◽  
S. Yip ◽  
D. Espinoza ◽  
J.F. Thompson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Phase 2 ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document